System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 6 citations

PubMed: 42023169 DOI: 10.1016/j.eclinm.2026.103884

Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.

EClinicalMedicine 95:103884

Authors: Boris Guiu, Clément Bailly, Eric Vibert, Ghoufrane Tlili, Denis Mariano-Goulart, Julien Edeline, Yann Touchefeu, Emmanuel Durand, Jean Frédéric Blanc, Julia Chalaye, Hélène Regnault, Antoine Bouvier, Geraldine Sergent, Christian Sengel, Stéphane Renaud, Agnès Rode, Claude Somma, Patrick Chevallier, Vincent Habouzit, Isabelle Brenot-Rossi, Anthony Dohan, Lambros Tselikas, Thierry DeBaère, Sylvain Manfredi, Arnaud Dieudonné, Kirk Fowers, Eveline Boucher, Binal Patel, Eric Vicaut, Etienne Garin

Affiliations

  • Hôpital Saint-Eloi, Montpellier, France.
  • Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France.
  • Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut-Lévêque, Bordeaux, France.
  • Centre Eugène Marquis, Rennes, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Créteil, France.
  • Centre Hospitalier Universitaire de Angers, Angers, France.
  • Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  • Centre Hospitalier Universitaire de Michallon, Grenoble, France.
  • Centre Hospitalier de Perpignan, Perpignan, France.
  • Hospices Civils de Lyon, Hôpital de la Croix Rousse, Lyon, France.
  • Centre Hospitalier Universitaire de la Timone, Hôpital Adultes, Marseille, France.
  • Centre Hospitalier Universitaire de Nice, Nice, France.
  • Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Saint-Étienne, France.
  • CLCC Institut Paoli-Calmettes, Marseille, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • Institut Gustave Roussy, Villejuif, France.
  • Centre Hospitalier Universitaire de Dijon, Université Bourgogne Europe, Dijon, France.
  • Centre Henri Becquerel, Rouen, France.
  • Boston Scientific Corporation, Malborough, MA, USA.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière - Fernand-Widal, Paris, France.

Abstract

BACKGROUND

Selective Internal Radiation Therapy with yttrium-90 (Y90) has been used for decades, yet guideline recommendations remain inconsistent. High-quality real-world data is needed to guide practice. The objectives of this study were to evaluate effectiveness, safety, and patient quality of life (QoL) with TheraSphere™ treatment in real-world clinical practice, and to identify clinical and dosimetric factors associated with survival.

METHODS

PROACTIF was a prospective, open label, non-interventional, all-comers cohort study that recruited patients who received Y90 glass microspheres (TheraSphere™) per local standard of care across 34 French sites (January 2019-January 2024). Co-primary endpoints were overall survival (OS) and QoL. Secondary endpoints included safety, conversion to surgery, and factors associated with OS. OS and time-to-deterioration in QoL (Functional Assessment of Cancer Therapy-Hepatobiliary) were assessed by Kaplan-Meier analysis. Adverse events were descriptively summarized using Common Terminology Criteria for Adverse Events, version 5. Trial registration: ClinicalTrials.gov Identifier, NCT04069468.

FINDINGS

Amongst 989 HCC patients, 13·3%/18·9%/57·9%/5·8% were Barcelona Clinic Liver Cancer (BCLC) A/B/C/D, respectively; 35·3% had portal-vein tumor thrombosis (PVT); 74·4% were treated using multicompartment dosimetry, and 53·6% with selective Y90 administration. Mean index lesion dose was 435·4 Gy. For all patients, median OS (mOS) [95% CI] was 21·8 months (M) [20·1-23·3]. mOS was 27·0 M [20·7-31·4] for BCLC B, 21·1 M [18·0-22·8] for BCLC C; 23·1 M [21·6-27·0] without PVT, 24·8 M [19·3-30·3] for patients with Vp1/Vp2; 16·8 M mOS for patients with a pretreatment absorbed dose to the index lesion <200 Gy versus 26·0 M with ≥200 Gy (p < 0·001); 19·7 M for <400 Gy and 30·7 M for ≥400 Gy (p < 0·001). After Y90, 106/989 (10·7%) underwent curative-intent surgery, resulting in a mOS of 48·6 M [40·6-not evaluable], versus 20·1 M [17·7-21·7] without surgery. Median time-to-deterioration in QoL was 10·6 M [9·6-11·7]. Serious adverse events occurred in 7·5% patients; serious treatment-related events in 3·7%.

INTERPRETATION

In this large real-world cohort, treatment with Y90 glass microspheres demonstrated favorable effectiveness and safety with meaningful outcomes, especially in PVT patients and following subsequent surgery. PROACTIF showed a strong dose-survival relationship as demonstrated in previous studies, and highlights the potential of a tumor absorbed dose ≥400 Gy to further increase survival. These findings support dosimetry-guided Y90 across all BCLC stages, and should inform future guideline recommendations.

FUNDING

Boston Scientific Corporation.

MeSH

Radiotherapy, Carcinoma, Hepatocellular, Safety, Glass, Microspheres, Neoplasms, Multiple Chronic Conditions, Therapeutics